|60.86|| +0.06 / +0.10%|
CSL Ltd. is a biopharmaceutical company. It engages in researches, develops, manufactures and markets vaccines and plasma protein biotherapies to treat and prevent human medical conditions. The company operates its business through two segments: CSL Behring and bioCSL. The CSL Behring segment provides plasma-derived and recombinant products, and operates plasma collection networks through CSL Plasma. The bioCSL segment manufactures, sells and distributes vaccines, antivenoms and other pharmaceutical products in Australia and New Zealand; and also manufactures and markets in vitro diagnostic products through Immunohaematology. It has manufacturing operations in Germany, Switzerland and the United States. The company was founded on November 2, 1961 and is headquartered in Parkville, Australia.
|Paul Roger Perreault||Chief Executive Officer, Executive Director & MD|
|David Mark Lamont||Chief Financial Officer|
|Andrew Cuthbertson||Chief Scientific Officer|
|Alan J. Wills||Senior VP-Strategy & Business Development|
|Mark Dehring||Head-Investor Relations|